Created at 11:49 a.m. Sep, 20, 2024
Author: musamalik
Related Note: 1496864629275 1
Rationale for change

Not sure where the info for this card came from but neither AMBOSS or FA mention IgG specifically - they just mention B cells, which would be all immunoobulins
Source: AMBOSS - https://next.amboss.com/us/article/qM0Cpg?q=rituximab#Ze00b1d8151bfbc4dd3b134e0567b0d43 and https://next.amboss.com/us/article/x50Emg?q=b%20cells#Q_XuL00

Text Text
Extra
Empty field
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Empty field
Additional Resources
Empty field
One by one
Empty field
#AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::04_Non_Hodgkin_Lymphoma_SOAP #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#OME::PreClinical::03_Immune::01_Immunology::16_Immunosuppression #AK_Step1_v12::#OME::03_Immune::01_Immunology::16_Immunosuppression #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::09_Plasma_Cell_Disorders #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::03_Kinase_Inhibitors_&_Monoclonal_Antibodies::02_Monoclonal_Antibody_Therapy::zanki_extra #AK_Step1_v12::#Bootcamp::Immunology::13_Transplant_Rejection::08_Biologic_Immunotherapy #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::19_Rituximab #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies::01_Autoimmune_disease_therapy::*Rituximab #PANCE::HEME::immunologic_disorders #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::18_Anticancer_monoclonal_antibodies::*Rituximab::Rituximab #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::04_Normocytic_Anemia::08_Autoimmune_Hemolytic_Anemia #AK_Other::Only_Step_1 #AK_Other::^EXPN #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::02_Anemia::06_Extravascular_Hemolytic_Anemia:_Intro_&_Extrinsic_DDx #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::06_Platelets::03_Platelet_Disorders #AK_Step1_v12::#Bootcamp::Musculoskeletal::15_Pharmacology::07_TNF_Alpha_Inhibitors_And_Monoclonal_Antibodies